US patients hospitalized for cirrhosis

Advances in Therapy

Volumn 30, Issue 1, 2013, Pages 71-80

  Deitelzweig, Steven ^a   Amin, Alpesh ^b   Christian, Rudell ^c   Friend, Keith ^c   Lin, Jay ^d   Lowe, Timothy J ^e  

^a OCHSNER MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^d Novosys Health   (United States)

^e Premier Inc   (United States)

Author keywords

Cirrhosis; Gastroenterology; Healthcare costs; Healthcare resource utilization; Hyponatremia; Length of stay; Re admission

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CHARLSON COMORBIDITY INDEX; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; EMERGENCY CARE; FEMALE; HEALTH CARE UTILIZATION; HOSPITAL COST; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITAL READMISSION; HOSPITAL UTILIZATION; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; HYPONATREMIA; INTENSIVE CARE UNIT; LENGTH OF STAY; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; MIDDLE AGED; MORTALITY; NEOPLASM; PROCEDURES; PROPENSITY SCORE; AGED; CASE CONTROL STUDY; ECONOMICS; HEALTH CARE COST; HEALTH CARE PLANNING; MULTIVARIATE ANALYSIS; STATISTICS AND NUMERICAL DATA; UNITED STATES; UTILIZATION; STATISTICS; UTILIZATION REVIEW;

ADULT; AGED; CASE-CONTROL STUDIES; COMORBIDITY; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HOSPITALIZATION; HUMANS; HYPONATREMIA; INTENSIVE CARE UNITS; LENGTH OF STAY; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT READMISSION; UNITED STATES;

EID: 84885894509     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-012-0073-1     Document Type: Article

References (21)

1. Sigal SH. Hyponatremia in cirrhosis. J Hosp Med. 2012;7(Suppl. 4):S14-7.
2. Angeli P, Wong F, Watson H, Ginès P; CAPPS Investigators. Hyponatremia in cirrhosis: Results of a patient population survey. Hepatology. 2006;44:1535-42.
3. Fisher RA, Heuman DM, Harper AM, et al. Region 11 MELD Na exception prospective study. Ann Hepatol. 2012;11:62-7.
4. Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359:1018-26.
5. Kim JH, Lee JS, Lee SH, et al. The association between the serum sodium level and the severity of complications in liver cirrhosis. Korean J Intern Med. 2009;24:106-12.
6. Kim WR, Brown RS Jr, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology. 2002;227-42.
7. Volk ML, Tocco RS, Bazick J, Rakoski MO, Lok AS. Hospital re-admissions among patients with decompensated cirrhosis. Am J Gastroenterol. 2012;107:247-52.
8. U.S. Department of Health and Human Services and National Institutes of Health. Action Plan for Liver Disease Research. NIH Publication No. 04-5491. 2004. Available at: http://www2.niddk.nih.gov/ AboutNIDDK/ResearchAndPlanning/ Liver-Disease/ Action-Plan-For-Liver-Disease-Intro.htm. Accessed May 21 2012.
9. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9- CM administrative databases. J Clin Epidemiol. 1992;45:613-9.
10. Nixon RM, Thompson SG. Parametric modeling of cost data in medical studies. Statist Med. 2004;23:1311-31.
11. Wald R, Jaber BL, Price LL, Upadhyay A, Madias NE. Impact of hospital-associated hyponatremia on selected outcomes. Arch Intern Med. 2010;170:294-302.
12. Jenq CC, Tsai MH, Tian YC, et al. Serum sodium predicts prognosis in critically ill cirrhotic patients. J Clin Gastroenterol. 2010;44:220-6.
13. Zhang JY, Qin CY, Jia JD, Wang BE. Serum sodium concentration profile for cirrhotic patients and its effect on the prognostic value of the MELD score. Zhonghua Gan Zang Bing Za Zhi. 2012;20:108-11.
14. Shorr AF, Tabak YP, Johannes RS, Gupta V, Saltzberg MT, Costanzo MR. Burden of sodium abnormalities in patients hospitalized for heart failure. Cong Heart Fail. 2011;17:1-7.
15. Zilberberg MD, Exuzides A, Spalding J, et al. Epidemiology, clinical and economic outcomes of admission hyponatremia among hospitalized patients. Curr Med Res Opin. 2008;24:1601-8.
16. Berman K, Tandra S, Forssell K, et al. Incidence and predictors of 30-day re-admission among patients hospitalized for advanced liver disease. Clin Gastroenterol Hepatol. 2011;9:254-9.
17. Cárdenas A, Ginès P, Marotta P, et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. J Hepatol. 2012;56:571-8.
18. Okita K, Sakaida I, Okada M, et al. A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis. J Gastroenterol. 2010;45:979-87.
19. Fábrega E, Berja A, García-Unzueta MT, et al. Influence of aquaporin-1 gene polymorphism on water retention in liver cirrhosis. Scand J Gastroenterol. 2011;46:1267-74.
20. Stone J, Hoffman, GJ. Medicare Hospital Readmissions: Issues, Policy Options and PPACA. (R40972). Washington, DC: Congressional Research Service. 2010. Available at: http://www. hospitalmedicine.org/AM/pdf/advocacy/CRS-Re- admissions-Report.pdf. Accessed May 5 2012.
21. American Hospital Association. Hospital statistics: 2012 edition. Chicago, IL: American Hospital Association; 2012.